Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy

Informazioni relative al progetto

VerSiLiB

ID dell’accordo di sovvenzione: 101046217

DOI

10.3030/101046217

Progetto chiuso

Data della firma CE 21 Marzo 2022

Data di avvio 1 Aprile 2022

Data di completamento 31 Marzo 2026

Finanziato da

• The European Innovation Council (EIC)

Costo totale

€ 2 994 244,99

Contributo UE

€ 2 994 244,99

Coordinato da

TEKNOLOGIAN TUTKIMUSKESKUS VTT OY
Finland

Periodic Reporting for period 2 - VerSiLiB (Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy)

Periodo di rendicontazione: 2023-04-01 al 2024-09-30

Sintesi del contesto e degli obiettivi generali del progetto

Project aims to develop a proof-of-concept of a novel in-vitro diagnostic system that combines the analysis of DNA and protein biomarkers into one proteogenomic test. Project is the first step to enable fast and easy-to-use proteogenomic tests that will be widely applicable in the diagnosis of several significant diseases including viral outbreaks, cancers, and neuro-degenerative, immune and cardiovascular diseases. In the end of the project, the developed technology will be validated for real-life cancer management in a clinical setting.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Work during the first 2.5 years of the project has focused on:
• Defining system specifications
• Development of the sensor test chemistry for protein and DNA assay
• Design and implementation of the second version of the microfluidic chip
• Design and development of the integrated hardware prototype
• Conducting simulations and theoretical analyses
• Development of reference tests and standards of truths
• Collection of clinical samples

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Work to develop diagnostic system based on novel Affinity Mediated Transport amplification method has continued in close collaboration of the highly multi-disciplinary consortium combining expertise in molecular biology, chemistry, physical sciences, engineering, and medicine. During the 2.5 years of the project, the consortium has focused on finding solutions to the joint challenges with test chemistry and hardware design. Once the system is successfully developed and its foreseen advantages are demonstrated, it has potential to impact widely to the proteogenomic analyses in medical but also in other application fields utilizing molecular analysis.